Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Decheng Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
Decheng Capital

Decheng Capital

Operating

Decheng Capital: A leading venture capital firm, investing in early and growth-stage healthcare and life sciences.

Location
Menlo Park, CA, US
Founded
2012
Firm
Compare
Portfolio
Employees
Website

Decheng Capital is a prominent venture capital firm specializing in early and growth-stage investments within the healthcare and life sciences sectors. With over $440 million in capital under management, Decheng Capital focuses on companies with revolutionary technologies and strong market presence. Their typical investment rounds include Series A, B, and C, reflecting their commitment to nurturing companies through critical growth phases.

Notable portfolio companies include Aadi Bioscience, Adela, Alpine Immune Sciences, and Arcus Biosciences, among others. Decheng Capital's investment philosophy emphasizes strategic support and capital infusion to help build legendary companies. The firm offers unique value-add services such as deep industry expertise and a robust network to accelerate the growth of their portfolio companies. Key partners and decision-makers at Decheng bring extensive experience from leading institutions in the life sciences sector.

Decheng Capital - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments45
Current Portfolio Count27
Total Portfolio Exits4

Top Investment Stages

Series B15 (36.6%)
Series A12 (29.3%)
Series C7 (17.1%)
Series Unknown4 (9.8%)
Post Ipo Equity3 (7.3%)

Stage Mix

Series B 37%Series A 29%Series C 17%Series Unknown 10%Post Ipo Equity 7%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Nalu Medical logo

Nalu Medical

Adela logo

Adela

Cellares logo

Cellares

Upstream Bio logo

Upstream Bio

VintaBio logo

VintaBio

LevitasBio logo

LevitasBio

Watchmaker Genomics logo

Watchmaker Genomics

Mirvie logo

Mirvie

Solve Therapeutics logo

Solve Therapeutics

Immpact Bio logo

Immpact Bio

Alpine Immune Sciences logo

Alpine Immune Sciences

Mammoth Biosciences logo

Mammoth Biosciences

Shape Therapeutics logo

Shape Therapeutics

Xtremity logo

Xtremity

PackGene Biotech logo

PackGene Biotech

Neurelis logo

Neurelis

Equillium logo

Equillium

Encodia logo

Encodia

GeneDx Holdings logo

GeneDx Holdings

VelosBio logo

VelosBio

Polares logo

Polares

Zepto logo

Zepto

AnHeart Therapeutics logo

AnHeart Therapeutics

Terns Pharmaceuticals logo

Terns Pharmaceuticals

Mindstrong logo

Mindstrong

Decheng Capital - Classification

Also Known As
  • Decheng Capital LLC
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end